Active site variability of type 1 11β-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

被引:30
作者
Hult, M
Shafqat, N
Elleby, B
Mitschke, D
Svensson, S
Forsgren, M
Barf, T
Vallgårda, J
Abrahmsen, L
Oppermann, U [1 ]
机构
[1] Karolinska Inst, SE-17177 Stockholm, Sweden
[2] Biovitrum AB, Dept Assay Dev & Screening, Dept Struct Chem, SE-11276 Stockholm, Sweden
[3] Univ Oxford, Struct Genom Consortium, Oxford OX1 2JD, England
关键词
11 beta-hydroxysteroid dehydrogenase; pre-receptor control; glucocorticoid metabolism; metabolic disease; insulin resistance; short-chain dehydrogenases/reductases;
D O I
10.1016/j.mce.2005.11.043
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The NADPH-dependent enzyme type 1 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1) activates in a tissue-specific manner circulating pro-glucocorticoid hormones (cortisone in humans) to the 11 beta-OH ligand (cortisol in humans), which is able to bind to its cognate receptor and regulate gene transcription. Modulation of this pre-receptor activation mechanism by selective enzyme inhibitors is a desirable goal in the treatment of insulin resistance and related metabolic disorders. Like most other hydroxysteroid dehydrogenases 11 beta-HSD1 belongs to the evolutionarily conserved enzyme superfamily of short-chain dehydrogenases/reductases (SDR). The enzyme is anchored within the endoplasmic, reticulum through an N-terminal transmembrane domain. In this study we aimed to characterize the active site of mammalian 11 beta-HSD1 by determining primary structures from several mammalian lines (cat, hamster, cynomolgus, chimpanzee, dog) thus increasing substantially available sequence information, and allowing us to determine highly variable and constant parts within the primary structure. These regions were mapped to the recently determined three-dimensional structure and are mostly found around the substrate binding site. Furthermore we performed inhibition studies by using different series of inhibitors, comprising 11 beta-HSD1 selective arylsulfonamidothiazoles and the unselective steroid-based compound carbenoxolone. The different arylsulfonamidothiazoles display distinct inhibition profiles versus the mammalian species tested, with several tight binding inhibitors for the human enzyme (K-i similar to 50 nM), intermediate for mouse, and weak or not binding inhibitors for rat and guinea pig (K-i > 3 mu M). Analysis of the inhibition mode reveals that the tight binding inhibitor BVT.528 is a competitive inhibitor for the human form, whereas the related compound BVT.2733 displays a mixed-type inhibition pattern versus the mouse enzyme. Taken together, this structure-activity study provides increased insight into active site complexity and catalytic mechanism of 11 beta-HSD1, useful for further inhibitor design. beta 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:26 / 33
页数:8
相关论文
共 34 条
[1]   Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains [J].
Alberts, P ;
Nilsson, C ;
Selén, G ;
Engblom, LOM ;
Edling, NHM ;
Norling, S ;
Klingström, G ;
Larsson, C ;
Forsgren, M ;
Ashkzari, M ;
Nilsson, CE ;
Fiedler, M ;
Bergqvist, E ;
Öhman, B ;
Björkstrand, E ;
Abrahmsén, LB .
ENDOCRINOLOGY, 2003, 144 (11) :4755-4762
[2]   Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice [J].
Alberts, P ;
Engblom, L ;
Edling, N ;
Forsgren, M ;
Klingström, G ;
Larsson, C ;
Rönquist-Nii, Y ;
Öhman, B ;
Abrahmsén, L .
DIABETOLOGIA, 2002, 45 (11) :1528-1532
[3]   Effects of the 11β-hydroxysteroid dehydrogrenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes [J].
Andrews, RC ;
Rooyackers, O ;
Walker, BR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :285-291
[4]   Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs.: Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1 [J].
Barf, T ;
Vallgårda, J ;
Emond, R ;
Häggström, C ;
Kurz, G ;
Nygren, A ;
Larwood, V ;
Mosialou, E ;
Axelsson, K ;
Olsson, R ;
Engblom, L ;
Edling, N ;
Rönquist-Nii, Y ;
Öhman, B ;
Alberts, P ;
Abrahmsén, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3813-3815
[5]   11β-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes:: From de-activation to generation of cortisol [J].
Bujalska, IJ ;
Walker, EA ;
Tomlinson, JW ;
Hewison, M ;
Stewart, PM .
ENDOCRINE RESEARCH, 2002, 28 (04) :449-461
[6]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]  
Copeland R. A., 2004, ENZYMES PRACTICAL IN
[8]   Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets [J].
Davani, B ;
Khan, A ;
Hult, M ;
Mårtensson, E ;
Okret, SE ;
Efendic, S ;
Jörnvall, H ;
Oppermann, UCT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (45) :34841-34844
[9]   Critical residues for structure and catalysis in short-chain dehydrogenases/reductases [J].
Filling, C ;
Berndt, KD ;
Benach, J ;
Knapp, S ;
Prozorovski, T ;
Nordling, E ;
Ladenstein, R ;
Jörnvall, H ;
Oppermann, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25677-25684
[10]   Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes [J].
Holmes, MC ;
Kotelevtsev, Y ;
Mullins, JJ ;
Seckl, JR .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 171 (1-2) :15-20